Predictable really.
After the recent flurry of big deals in the pharmaceutical sector - think Pfizer’s $68bn bid for Wyeth, Roche’s $47bn offer for the chunk of Genentech it did not already own and Merck’s $41bn takeover of Schering-Plough - it was only a matter of time before the rumour mill started to whirl into action.
And how. First there is talk that GlaxoSmithKline is lining up a bid for Allergan, the botox specialist listed on the NYSE which has a market value pf over $13bn, and then there is speculation that Baxter is eyeing Stryker, another medical devices company.
More from the FT
No comments:
Post a Comment